Skip to content

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, Luis G Paz-Ares, Leora Horn, David Robert Spigel, Martin B. Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Oscar G. Arrieta, Jérôme Fayette, H. Léna, Elena V Poddubskaya, David E. Gerber, Scott N. Gettinger, Charles M. Rudin, Naiyer A. Rizvi, George R. Blumenschein, Scott Joseph Antonia, Cécile Dorange, Christopher T. Harbison, F. Graf Finckenstein, Julie Renee Brahmer

New England Journal of Medicine · 2015 · 9,473 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Borghaei, H., Paz-Ares, L. G., Horn, L., Spigel, D. R., Steins, M. B., Ready, N., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlési, F., Kohlhäufl, M., Arrieta, O. G., Burgio, M. A., Fayette, J., Léna, H., Poddubskaya, E. V., Gerber, D. E., Gettinger, S. N., … Brahmer, J. R. (2015). Nivolumab versus docetaxel in advanced nonsquamous Non–Small-Cell lung cancer. New England Journal of Medicine, 373(17), 1627–1639. https://doi.org/10.1056/nejmoa1507643

In text: (Borghaei et al., 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: Overall survival was longer with nivolumab than with docetaxel. The median overall survival was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 months (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P=0.002). At 1 year, the overall survival rate was 51% (95% CI, 45 to 56) with nivolumab versus 39% (95% CI, 33 to 45) with docetaxel. With additional follow-up, the overall survival rate at 18 months was 39% (95% CI, 34 to 45) with nivolumab versus 23% (95% CI, 19 to 28) with docetaxel. The response rate was 19% with nivolumab versus 12% with docetaxel (P=0.02). Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively), the rate of progression-free survival at 1 year was higher with nivolumab than with docetaxel (19% and 8%, respectively). Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1%, ≥5%, and ≥10%) of the PD-1 ligand. Treatment-related adverse events of grade 3 or 4 were reported in 10% of the patients in the nivolumab group, as compared with 54% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).

  1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
  3. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
  4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016

Metadata from OpenAlex (CC0). Citations are generated from the published record.